The countdown is on: New EU Variation Classification Guideline for medicinal products for human use – are you prepared?

The year 2025 is drawing to a close and the deadline for the application of the new version of the EU Variation Classification Guideline for medicinal products for human use is fast approaching. While the updated EU Variation Regulation (EC) 1234/2008 has already introduced procedural changes since 1 January 2025, the new rules for classifying variations will become binding from 15 January 2026, without a transition period. It is therefore high time to familiarise yourself with the changes and start strategic planning for upcoming submissions.

Following the entry into force of the updated EU Variation Regulation 1234/2008 on 1 January 2025, which introduced innovations such as the annual update for Type IA variations and mandatory worksharing for Type IB and Type II variations, new regulations on the classification of variations are now being introduced.

From 15 January 2026, variations may only be classified in accordance with the updated version of the "Guideline on the details of the various categories of variation, on the operation of the procedures laid down in Chapters II, IIa, III and IV of Commission Regulation (EC) No 1234/2008 concerning the examination of variations to the terms of marketing authorisations for medicinal products for human use, and on the documentation to be submitted pursuant to those procedures", or "Variation Classification Guideline" for short. There will be no transition period.

So it's high time to familiarise yourself with the changes if you haven't already done so.

Here is a brief overview:

• The guideline now only applies to medicinal products for human use, and no longer to veterinary products.
• The letters of the change categories A (administrative changes), B (quality changes), C (safety, efficacy, pharmacovigilance changes) and D (PMF/VAMF) have been renamed E, Q, C and M.
• The wording for many change topics has been changed.
• For some change topics, the conditions for classification as a Type IA variation have been changed.
• In some cases, the requirements for the documentation to be submitted have been adjusted.
• The previously available "Article 5 recommendations" have been integrated into the Classification Guideline. In future, the guideline is to be updated at least annually with regard to these.
• When submitting applications in accordance with the new guidelines, the updated electronic application form (eAF), which has already been published as a test version, must be used.

It is therefore important to take a close look at the consequences of the new guideline for current changes to your products so that you do not encounter any unpleasant surprises in the course of your change management.

Please note the regulations for submissions around the deadline!

The deadline entails special regulations that must be observed differently depending on the type of variation. For Type IB and Type II variations, the submission date determines whether the previous or new Classification Guideline applies. Submissions up to 14 January 2026 must be classified according to the old Guideline, while the new regulations apply from 15 January 2026 onwards.

Type IA variations require special attention: for these, the implementation date is decisive for the required submission date. Changes that have been implemented up to and including 14 January 2026 must also be submitted by this date at the latest. If no regular annual update is due by then, the relevant variations should be submitted as part of an early annual update or as a separate variation.

So plan your submissions strategically and don't miss the deadline for compiling your documents so that you can complete all changes that have already been implemented in good time before the deadline!

TentaConsult: Your partner for successful implementation of the new Variation Classification Guideline!

The transition to the new EU Variation Classification Guideline requires in-depth knowledge of the changed classifications and strategically thought-out planning of all upcoming submissions, especially in the critical period around the deadline. TentaConsult provides comprehensive support to marketing authorisation holders of pharmaceutical products to ensure a smooth regulatory transition and compliance.

We are happy to assist you in organising, preparing and submitting your variations in the form of annual updates, super-groupings and worksharings, whereby we evaluate the strategically optimal assignment to old or new guidelines for your specific changes and assist you in compiling all necessary documents in a timely manner.

Did you know? We also offer online or in-house training for your employees, tailored specifically to your needs, to optimally prepare your team for the new terminology and changed classifications.

The countdown is on, so act now! Benefit from our comprehensive expertise in regulatory affairs and get in touch with us. Contact us today and ensure that your submissions are timely and compliant.